MInimal Residual Disease Adapted Strategy

NCT ID: NCT04934475

Last Updated: 2024-11-07

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 791 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-12-08
• Study Completion Date: 2028-09-30

Brief Summary

IFM 2020-02 will enroll patients eligible for ASCT less than 66 years. All patients will receive induction based on 6 cycles (28-day) of KRD-Isatuximab (Isa-KRD), in order to achieve deep responses and high MRD negativity rates. Patients will be classified at diagnosis according to cytogenetics (standard vs high-risk cytogenetics defined by the LP score including 17p deletion, t(4;14), del(1p32), gain 1q, trisomy 21 and trisomy 5).

Detailed Description

According to international guidelines, outside clinical trials, frontline autologous stem cell transplantation (ASCT) is the standard of care for fit patients less than 71 years of age, who are newly diagnosed with multiple myeloma.

Triplet combinations are now the backbone of induction therapy prior to ASCT. KRD (Carfilzomib, Lenalidomide, Dexamethasone) is potentially the more active regimen.

Quadruplet combinations are under evaluation. The prospective phase 3 CASSIOPEIA trial conducted by the IFM and HOVON cooperative groups investigated the outcome of transplant-eligible patients treated with VTD (Bortezomib, Thalidomide, Dexamethasone) +/- Daratumumab administered both before (induction, 4 cycles) and after (consolidation, 2 cycles) single ASCT prepared by Melphalan 200 mg/m2.5 The addition of Daratumumab to VTD during induction induced significantly higher response rates, but also higher minimal residual disease (MRD) - negativity rates. The high response rates achieved after induction (MRD negativity rates at 10-5 by 8-color flow cytometry 35% (188/543) in the VTD-Dara arm vs 23% (125/542) after 4 cycles of VTD in the intent-to-treat population), but also after consolidation and before maintenance (MRD negativity rates at 10-5 by 8-color flow cytometry 63% in the VTD-Dara arm vs 43% in the VTD in the intent-to-treat population), translated into a significant improvement in progression-free-survival (PFS) in the Daratumumab arm of the study: 18-month PFS 93% vs 85% before maintenance, HR 0.47 (0.33-0.67), p < 0.0001. Cassiopeia is the first study showing a correlation between MRD negativity after induction (before ASCT) and PFS benefit, in the setting of quadruplet combination induction. Based on these results, VTD + daratumumab was recently approved by the FDA and EMA.

KRD has also been combined with Daratumumab in several phase 2 trials. Early results indicate that this quadruplet combination might potentially be the most effective regimen prior to ASCT in terms of response and MRD-negativity rates. Carfilzomib was administered intravenously weekly, on days 1, 8 and 15 of 28 day-cycles at the dose of 56 mg/m². Based on 70 patients, the MRD-negativity rate after four cycles of KRD-Daratumumab was 39% at a detection level of 10-5 by next generation sequencing (NGS). The weekly KRD-Daratumumab regimen was associated with low toxicity, and stem cell harvest was adequate. The rate of MRD negativity in 42 patients further improved after single ASCT, to 67% and 43% at a detection level of 10-5 and of 10-6 by NGS, respectively. Due to the short 7.9 months median follow-up time at the time of presentation, no PFS data were presented. At ASCO 2020, Weisel et al reported the results of induction based on 6 cycles of KRD plus Isatuximab, in patients with high-risk cytogenetics.8 In this interim analysis on the first 46 patients eligible for ASCT with high-risk disease, the overall response rate was 100%, including 60% MRD negativity at 10-5 by NGS after induction and before ASCT. No death on study was reported. No data are yet available regarding MRD negativity rates after ASCT or PFS. At ASH 2019, Landgren et al. reported the results of eight weekly KRD-Daratumumab cycles without ASCT in a small phase 2 study on 41 patients after a short median follow-up time of 8.6 months.

On the same intent-to-treat basis, MRD-negativity rate at a detection level of 10-5 by NGS was 61% and 65% in patients after six and eight cycles, respectively, including a very good partial response (VGPR) rate or better of 85% after 8 cycles and an overall response rate (ORR) of 100%. No death on study was seen. At the time of the report, no patient with MRD-negative disease had progressed. Despite the short follow-up time, based on the high rate of MRD-negativity and the 0% relapse rate achieved so far with this quadruplet combination, the authors of this small phase 2 series now propose to systematically delay ASCT in patients with standard-risk disease. This provocative recommendation requires validation in a phase 3 randomized trial comparing frontline versus delayed ASCT in patients with MRD-negative disease after induction.

Patients MRD positive after quadruplet induction are at higher risk of disease progression. For patients with high-risk (HR) disease, tandem ASCT has been proposed in order to improve PFS and overall survival (OS). In an integrated analysis of four phase III studies independently conducted by HOVON/GMMG, IFM, PETHEMA/GEM and GIMEMA European cooperative groups, in the era of Bortezomib-based induction regimens, double ASCT significantly improved PFS and OS in HR patients.

In the EMN02/HO95 study, in centers with a policy of double ASCT, patients were assigned to receive VMP (Bortezomib, Melphalan, Prednisone), single ASCT (ASCT-1) or two planned ASCTs (ASCT-2) to prospectively compare ASCT-1 with ASCT-2. Patients who received ASCT-2 had a prolonged PFS compared to those who received ASCT-1. Importantly, ASCT-2 overcame the adverse prognosis conferred by high-risk cytogenetics. In the same study, OS from the first randomization was significantly prolonged with ASCT-2 as compared with ASCT-1, a benefit also seen in subgroups of patients with adverse prognosis, including those with R-ISS stage II+III and high-risk cytogenetics. To date, no prospective trial has compared single vs tandem ASCT in HR patients in the era of quadruplet induction combinations.

After ASCT, a systematic maintenance is recommended by International Guidelines. Lenalidomide is approved in this setting, and proposed until progression. Other agents or combinations are under evaluation for maintenance, such as Ixazomib, Elotuzumab, Daratumumab or Isatuximab. Iberdomide is a next generation cereblon targeting agent, with antitumor and immunostimulatory activities in Lenalidomide- and Pomalidomide-resistant multiple myeloma. This oral agent, which could be the ideal agent for maintenance therapy, is currently tested after ASCT. Phase 2 and 3 randomized studies are currently investigating the combination of Lenalidomide with anti-CD38 monoclonal antibodies as maintenance therapy after autologous stem cell transplant. We assume that a fixed duration of maintenance using Iberdomide and Isatuximab will induce a high-rate of sustained MRD negativity.

Conditions

Multiple Myeloma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: FACTORIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

MRD Standard-risk patients (post induction MRD <10-5, MRD SR) (1:1 Randomization) : Arm A

Arm A: consolidation with 6 additional cycles of Isa-KRD (cycles 7 to 12; 28-day cycle; Isa-KRD = Isatuximab Carfilzomib Lenalidomide Dexamethasone):

• Isatuximab: 10 mg/kg I.V. on days 1 and 15 (cycles 7 to 12)
• Carfilzomib: 56 mg/m2 I.V on days 1, 8 and 15 (cycles 7 to 12)
• Lenalidomide: 25 mg per day orally from days 1 to 21
• Dexamethasone: 40 mg orally on day 1, 8, 15, 22

Group Type: EXPERIMENTAL

Isatuximab

Intervention Type: DRUG

Treatment with Isa-KRD during induction and consolidation , with Lenalidomide (Revlimid) or Iberdomide + Isatuximab during maintenance phase

MRD Standard-risk patients (post induction MRD <10-5, MRD SR) (1:1 Randomization): Arm B

Arm B: consolidation with ASCT followed by 2 cycles of Isa-KRD (cycles 7 and 8; Isa-KRD = Isatuximab Carfilzomib Lenalidomide Dexamethasone; 28-day cycle) Melphalan 200 mg/m2 followed by autologous stem cell transplantation (please refer to section 6.3.2)

• Isatuximab: 10 mg/kg I.V. on days 1 and 15 (cycles 7 to 8)
• Carfilzomib: 56 mg/m2 I.V on days on days 1, 8 and 15 (cycles 7 to 8)
• Lenalidomide: 25 mg per day orally from days 1 to 21
• Dexamethasone: 40 mg orally on days 1, 8, 15, 22 (cycles 7 to 8)

Group Type: EXPERIMENTAL

Isatuximab

Intervention Type: DRUG

Treatment with Isa-KRD during induction and consolidation , with Lenalidomide (Revlimid) or Iberdomide + Isatuximab during maintenance phase

ASCT

Intervention Type: PROCEDURE

ASCT for ams B, C and D during consolidation

MRD High-risk patients (post induction MRD >10-5, MRD HR) (1:1 Randomization): Arm C

Arm C: ASCT followed by 2 cycles of Isa-KRD (cycles 7 and 8; Isa-KRD = Isatuximab Carfilzomib Lenalidomide Dexamethasone; 28-day cycle) Melphalan 200 mg/m2 followed by autologous stem cell transplantation.

• Isatuximab: 10 mg/kg I.V. on days 1 and 15 (cycles 7 to 8)
• Carfilzomib: 56 mg/m2 I.V on days on days 1, 8 and 15 (cycle 7 to 8)
• Lenalidomide: 25 mg per day orally from day 1 to day 21
• Dexamethasone: 40 mg orally on days 1, 8, 15, 22 (cycle 7 to 8)

Group Type: EXPERIMENTAL

Isatuximab

Intervention Type: DRUG

Treatment with Isa-KRD during induction and consolidation , with Lenalidomide (Revlimid) or Iberdomide + Isatuximab during maintenance phase

ASCT

Intervention Type: PROCEDURE

ASCT for ams B, C and D during consolidation

MRD High-risk patients (post induction MRD >10-5, MRD HR) (1:1 Randomization): Arm D

Tandem ASCT Melphalan 200 mg/m2 followed by autologous stem cell transplantation.

Group Type: EXPERIMENTAL

ASCT

Intervention Type: PROCEDURE

ASCT for ams B, C and D during consolidation

Interventions

Isatuximab

Treatment with Isa-KRD during induction and consolidation , with Lenalidomide (Revlimid) or Iberdomide + Isatuximab during maintenance phase

Intervention Type: DRUG

ASCT

ASCT for ams B, C and D during consolidation

Intervention Type: PROCEDURE

Other Intervention Names

Carfilzomib; Revlimid; Dexamethasone

Eligibility Criteria

Inclusion Criteria

1. Male or female subjects, 18 years of age or older, younger than 66 years (< 66 years)

2. Voluntary written informed consent must be given before performance of any study-related procedure not part of normal medical care, with the understanding that the subject may withdraw consent at any time without prejudice to future medical care.

3. Subject must have documented multiple myeloma satisfying the CRAB and measurable disease as defined by:

1. Monoclonal plasma cells in the bone marrow ≥ 10% or presence of a biopsy proven plasmacytoma AND any one or more of the following myeloma defining events:

• Hypercalcemia: serum calcium > 0.25 mmol/L (> 1 mg/dL) higher than ULN or > 2.75 mmol/L (> 11 mg/dL)
• Renal insufficiency: creatinine clearance < 40mL/min or serum creatinine > 177 μmol/L (> 2 mg/dL)
• Anemia: hemoglobin > 2 g/dL below the lower limit of normal or hemoglobin < 10 g/dL
• Bone lesions: one or more osteolytic lesions on skeletal radiography, CT or PET-CT
• Clonal bone marrow plasma cell percentage ≥ 60%
• Involved: uninvolved serum free light chain ratio ≥ 100
• Superior 1 focal lesion on MRI studies

2. Measurable disease as defined by the following:

• M-component ≥ 5g/L, and/or urine M-component ≥ 200 mg/24h and/or serum FLC ≥ 100 mg/L

4. Newly diagnosed subjects eligible for high dose therapy and autologous stem cell transplantation

5. Karnofsky performance status score ≥ 50% (eastern cooperative oncology group performance status ECOG score ≤ 2)

6. Subject must have pretreatment clinical laboratory values meeting the following criteria during the Screening Phase (Lab tests should be repeated if done more than 15 days before C1D1):

1. Hemoglobin ≥ 7.5 g/dL (≥ 5mmol/L). Prior red blood cell [RBC] transfusion or recombinant human erythropoietin use is permitted;

2. Absolute neutrophil count (ANC) ≥ 1.0 Giga/L (GCSF use is permitted);

3. ASAT ≤ 3 x ULN;

4. ALAT ≤ 3 x ULN;

5. Total bilirubin ≤ 3 x ULN (except in subjects with congenital bilirubinemia, such as Gilbert syndrome, direct bilirubin ≤ 1.5 x ULN);

6. Calculated creatinine clearance ≥ 40 mL/min/1.73 m²;

7. Corrected serum calcium ≤ 14 mg/dL (< 3.5 mmol/L); or free ionized calcium ≤6.5 mg/dL (≤ 1.6 mmol/L);

8. Platelet count ≥ 50 Giga/L for subjects in whom < 50% of bone marrow nucleated cells are plasma cells; otherwise platelet count > 50 Giga/L (transfusions are not permitted to achieve this minimum platelet count).

7. Women of childbearing potential must have a negative serum or urine pregnancy test within 10 to 14 days prior to therapy and repeated within 24 hours before starting study drug. They must commit to continued abstinence from heterosexual intercourse or begin 2 acceptable methods of birth control (One highly effective method and one additional effective method) used at the same time, beginning at least 4 weeks before initiation of Lenalidomide treatment and continuing for at least 30 days after the last dose of Lenalidomide, Iberdomide and 5 months after last dose of Isatuximab. Women must also agree to notify pregnancy during the study.

8. Men must agree to not father a child and agree to use a latex condom during therapy and during dose interruptions and for at least 90 days after the last dose of study drug including Lenalidomide and Iberdomide and 5 months after last dose of Isatuximab, even if they have had a successful vasectomy, if their partner is of childbearing potential. Patient must also refrain from donating sperm during this period.

Exclusion Criteria

1. Subjects must not have been treated previously with any systemic therapy for multiple myeloma. Prior treatment with corticosteroids or radiation therapy does not disqualify the subject (the maximum dose of corticosteroids should not exceed the equivalent of 160 mg of dexamethasone in a 2-week period). Two weeks must have elapsed since the date of the last radiotherapy treatment. Enrolment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 2 weeks have elapsed since the last date of therapy.

2. Subject has a diagnosis of primary amyloidosis, monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or solitary plasmacytoma.

3. Subject has a diagnosis of Waldenström's macroglobulinemia, or other conditions in which IgM M-protein is present in the absence of a clonal plasma cell infiltration with lytic bone lesions.

4. Subject has had plasmapheresis within 14 days of C1D1.

5. Subject is exhibiting clinical signs of meningeal involvement of multiple myeloma.

6. Myocardial infarction within 4 months prior to enrolment according to NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities

7. Uncontrolled hypertension

8. Subjects with a history of moderate or severe persistent asthma within the past 2 years, or with uncontrolled asthma of any classification at the time of screening (Note that subjects who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed in the study).

9. Intolerance to hydration due to pre-existing pulmonary or cardiac impairment.

10. Subject has plasma cell leukemia (according to WHO criterion: ≥ 20% of cells in the peripheral blood with an absolute plasma cell count of more than 2 × 109/L) or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes).

11. Any clinically significant, uncontrolled medical conditions that, in the Investigator's opinion, would expose the patient to excessive risk or may interfere with compliance or interpretation of the study results.

12. Systemic treatment with strong inhibitors of CYP1A2 (fluvoxamine, enoxacin), strong inhibitors of CYP3A (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort within 14 days before the first dose of study treatment.

13. Known intolerance to steroid therapy, mannitol, pregelatinized starch, odium stearyl fumarate, histidine (as base and hydrochloride salt), arginine hydrochloride, poloxamer 188, sucrose or any of the other components of study intervention that are not amenable to premedication with steroids and H2 blockers or would prohibit further treatment with these agents.

14. History of allergy to any of the study medications, their analogues, or excipients in the various formulations

15. Subject has had major surgery within 2 weeks before study inclusion (informed consent signature) or will not have fully recovered from surgery, or has surgery planned during the time the subject is expected to participate in the study. Kyphoplasty or Vertebroplasty are not considered major surgery.

16. Clinically relevant active infection or serious co-morbid medical conditions

17. Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical, breast or prostate cancer free of disease since 5 years.

18. Female subject who is pregnant or breast-feeding

19. Serious medical or psychiatric illness likely to interfere with participation in study

20. Uncontrolled diabetes mellitus

21. Known HIV infection; Known active hepatitis A, B or C viral infection

22. Uncontrolled or active HBV infection: Patients with positive HBsAg and/or HBV DNA

Of note:

• Patient can be eligible if anti-HBc IgG positive (with or without positive anti-HBs) but HBsAg and HBV DNA are negative.
• If anti-HBV therapy in relation with prior infection was started before initiation of IMP, the anti-HBV therapy and monitoring should continue throughout the study treatment period.
• Patients with negative HBsAg and positive HBV DNA observed during screening period will be evaluated by a specialist for start of anti-viral treatment: study treatment could be proposed if HBV DNA becomes negative and all the other study criteria are still met.

23. Active HCV infection: positive HCV RNA and negative anti-HCV

Of note:

• Patients with antiviral therapy for HCV started before initiation of IMP and positive HCV antibodies are eligible. The antiviral therapy for HCV should continue throughout the treatment period until seroconversion.
• Patients with positive anti-HCV and undetectable HCV RNA without antiviral therapy for HCV are eligible.

24. Active systemic infection and severe infections requiring treatment with a parenteral administration of antibiotics.

25. Incidence of gastrointestinal disease that may significantly alter the absorption of oral drugs

26. Subjects unable or unwilling to undergo antithrombotic prophylactic treatment

27. Person under guardianship, trusteeship or deprived of freedom by a judicial or administrative decision

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 66 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Amgen

INDUSTRY

Sponsor Role: collaborator

Sanofi

INDUSTRY

Sponsor Role: collaborator

Bristol-Myers Squibb

INDUSTRY

Sponsor Role: collaborator

Intergroupe Francophone du Myelome

NETWORK

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Philippe Moreau, Professor

Role: PRINCIPAL_INVESTIGATOR

Nantes University Hospital

Locations

Institut Jules Bordet

Brussels, , Belgium

Cliniques Universitaires Saint-Luc

Brussels, , Belgium

Grand Hôpital de Charleroi - Site de Notre-Dame

Charleroi, , Belgium

Hôpital Jolimont

Haine-Saint-Paul, , Belgium

CHU de Liège

Liège, , Belgium

CHU UCL Namur (Site Godinne)

Yvoir, , Belgium

CHU Amiens Sud

Amiens, , France

CHRU-Hôpital du Bocage

Angers, , France

Centre Hospitalier d'Argenteuil Victor Dupouy

Argenteuil, , France

Centre Hospitalier H.Duffaut

Avignon, , France

Centre hospitalier de la Côte Basque

Bayonne, , France

Hôpital Jean Minjoz

Besançon, , France

Centre Hospitalier Simone Veil

Blois, , France

Hôpital Avicenne

Bobigny, , France

Polyclinique Bordeaux Nord Acquitaine

Bordeaux, , France

CHRU Hôpital Haut Lévêque - Centre François Magendie

Bordeaux Pessac, , France

Hôpital de Fleyriat

Bourg-en-Bresse, , France

CHRU Brest - Hôpital A. Morvan

Brest, , France

CHU Caen - Côte de Nacre

Caen, , France

CH René Dubos

Cergy-Pontoise, , France

Centre Hospitalier William Morey

Chalon-sur-Saône, , France

CH Chambéry

Chambéry, , France

Hôpital d'Instruction des Armées Percy

Clamart, , France

Chu Estaing

Clermont-Ferrand, , France

Centre Hospitalier Sud Francilien

Corbeil-Essonnes, , France

CHU Henri Mondor

Créteil, , France

CHU Dijon Hôpital d'enfants

Dijon, , France

Centre Hospitalier Général

Dunkirk, , France

CHRU Hôpital A. Michallon

Grenoble, , France

CHD Vendée

La Roche-sur-Yon, , France

CHV André Mignot - Université de Versailles

Le Chesnay, , France

CH de Chartres - Hôpital Louis Pasteur

Le Coudray, , France

Hôpital Jacques Monod

Le Havre, , France

Centre Hospitalier

Le Mans, , France

CHRU Hôpital Claude Huriez

Lille, , France

GH de l'Institut Catholique Saint Vincent

Lille, , France

Centre Hospitalier Universitaire (CHU) de Limoges

Limoges, , France

Hôpital du Scorff

Lorient, , France

Centre Léon Bérard

Lyon, , France

Institut Paoli Calmettes

Marseille, , France

CH Meaux

Meaux, , France

Hôpital de Mercy (CHR Metz-Thionville)

Metz, , France

Hopital Saint Eloi - CHU Montpellier

Montpellier, , France

Hôpital E. Muller

Mulhouse, , France

CHRU Hôtel Dieu

Nantes, , France

Clinique de l'Archet

Nice, , France

CHU Carémeau

Nîmes, , France

CH La Source

Orléans, , France

CHU Hôpital Saint Antoine

Paris, , France

Hôpital Cochin

Paris, , France

Hôpital Necker

Paris, , France

Hôpital Saint Louis

Paris, , France

Institut Curie

Paris, , France

La Pitié- Salpetrière

Paris, , France

CH Saint Jean

Perpignan, , France

Centre Hospitalier de Perigueux

Périgueux, , France

Hospices Civils de Lyon - Hôpital Lyon Sud

Pierre-Bénite Lyon, , France

CHU Poitiers - Pôle régional de Cancérologie

Poitiers, , France

Ch Annecy Genevois

Pringy, , France

Centre Hospitalier Intercommunal de Cornouaille

Quimper, , France

Hôpital Robert Debré

Reims, , France

CHRU Hôpital de Pontchaillou

Rennes, , France

Centre Henri Becquerel

Rouen, , France

Centre Hospitalier Yves Le Foll

Saint-Brieuc, , France

Institut de Cancérologie Lucien Neuwirth

Saint-Priest-en-Jarez, , France

Centre Hospitalier de Saint-Quentin

Saint-Quentin, , France

Hôpitaux Universitaires de Strasbourg - Hôpital de Hautepierre

Strasbourg, , France

Pôle IUCT Oncopole CHU

Toulouse, , France

CHRU Hôpital Bretonneau

Tours, , France

CHRU Hôpitaux de Brabois

Vandœuvre-lès-Nancy, , France

CHBA

Vannes, , France

Gustave Roussy

Villejuif, , France

CHU de La Réunion site Sud

Saint-Pierre, , Reunion

Countries

Belgium; France; Reunion

References

Perrot A, Lambert J, Hulin C, Pieragostini A, Karlin L, Arnulf B, Rey P, Garderet L, Macro M, Escoffre-Barbe M, Gay J, Chalopin T, Gounot R, Schiano JM, Mohty M, Leleu X, Manier S, Mariette C, Chaleteix C, Braun T, De Prijck B, Avet-Loiseau H, Mary JY, Corre J, Moreau P, Touzeau C; MIDAS Study Group. Measurable Residual Disease-Guided Therapy in Newly Diagnosed Myeloma. N Engl J Med. 2025 Jul 31;393(5):425-437. doi: 10.1056/NEJMoa2505133. Epub 2025 Jun 3.

Reference Type: DERIVED

PMID: 40459097 (View on PubMed)

Perrot A, Touzeau C, Lambert J, Hulin C, Caillot D, Karlin L, Arnulf B, Rey P, Garderet L, Macro M, Escoffre Barbe M, Gay J, Chalopin T, Gounot R, Schiano JM, Tiab M, Mohty M, Kuhnowski F, Fontan J, Manier S, Orsini-Piocelle F, Vincent L, Rigaudeau S, Leleu X, Hebraud B, Flet L, Malfuson JV, Jacquet C, Chaoui D, Meuleman N, Abarah W, Montes L, Benramdane R, Sonntag C, Zerazhi H, Danu A, Allangba O, Dib M, Roussel M, Cereja S, Depaus J, Branche N, Demarquette H, Richez V, Cherel B, Frenzel L, Vekemans MC, Bigot N, Avet-Loiseau H, Corre J, Moreau P. Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial. Blood. 2025 Jul 3;146(1):52-61. doi: 10.1182/blood.2024026230.

Reference Type: DERIVED

PMID: 39841461 (View on PubMed)

Mohan M, Gundarlapalli S, Szabo A, Yarlagadda N, Kakadia S, Konda M, Jillella A, Fnu A, Ogunsesan Y, Yarlagadda L, Thalambedu N, Munawar H, Graziutti M, Al Hadidi S, Alapat D, Thanendrarajan S, Zangari M, van Rhee F, Schinke C. Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma. Am J Hematol. 2022 Jun 1;97(6):E195-E198. doi: 10.1002/ajh.26530. Epub 2022 Mar 21. No abstract available.

Reference Type: DERIVED

PMID: 35285981 (View on PubMed)

Other Identifiers

2020-005216-21

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

IFM2020-02

Identifier Type: -

Identifier Source: org_study_id